Tirofiban 12.5mg/250ml infusion bags
Requires a prescription from a doctor or prescriber
Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Tirofiban
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Tirofiban
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Tirofiban
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
4 branded products available
MHRA licensed products
View all licensed products for Tirofiban on the MHRA register
Aggrastat 12.5mg/250ml infusion bags
Tirofiban 12.5mg/250ml infusion bags
Tirofiban 12.5mg/250ml infusion bags
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(1)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 41 · Randomised trials: 9 · 2001–2026
Showing the 50 most relevant studies, sorted by most relevant.
Zhong-Ming Qiu, Feng-Li Li, Hong-Fei Sang, et al.
JAMA, 2022
Michael A. Blazing
JAMA, 2004
Shatha Alqurashi, M. Alqahtani, S. Albeladi, et al.
Frontiers in Neurology, 2025
Mengmeng Wang, Jing Li, Ling-Yu Zhang, et al.
Frontiers in Neurology, 2024
Yu-Han Liu, Libin Zheng, Cheng-Cheng Zhang, et al.
The Journal of emergency medicine, 2024
Haiyan Xie, Ying Chen, Wukun Ge, et al.
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2023
Wen-Bo Zhao, Si-Jia Li, Chuan-Hui Li, et al.
JAMA neurology, 2024
Xiao Z, Hu X, Deng L, et al.
2026
- Intracranial Aneurysm
- Platelet Aggregation Inhibitors
- Endovascular Procedures
He Z, Huang X, Wei Y, et al.
2025
- Fibrinolytic Agents
- Platelet Aggregation Inhibitors
- Thrombolytic Therapy
Yu Y, Deng T, Jiang Y, et al.
2025
This meta-analysis aimed to evaluate the safety and efficacy of combining tirofiban with oral antiplatelet agents in treating patients with progressive ischemic stroke. The investigators searched several databases, including PubMed, Web of Science, the Cochrane Library, CNKI, VIP, WanFang Data and Sinomed. The search was restricted to literature published before May 5, 2025, without any language restrictions. Stata software 17.0 was used to analyze the results and assess risk of bias. A total of 19 studies comprising 3,667 patients were included in the analysis. Furthermore, statistically significant differences (P0.05) were detected in the risks of intracranial hemorrhage, other systemic hemorrhage, mortality rate and serious adverse events between the two groups. The study was conducted according to the preferred reporting items for systematic reviews and meta-analyses guidelines and registered with PROSPERO (no. CRD42025633357), and the findings suggested that tirofiban-augmented antiplatelet regimens safely improve clinical outcomes in progressive cerebral infarction, particularly when combined with dual oral antiplatelet agents.
Abstract licence: CC BY-NC-ND
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
44 found
Half-life
2 hours
Mechanism
Tirofiban is a reversible antagonist of fibrinogen binding to the GP IIb/IIIa re…
Food interactions
None known
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Half-life
2 hours
Protein binding
65%
Volume of distribution
22 to 42 L
Metabolism
Elimination
65%
Clearance
213 - 314 mL/min
* 152 - 267 mL/min [patients with coronary artery disease]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 995 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
* 152 - 267 mL/min [patients with coronary artery disease]
Proteins and enzymes this drug interacts with in the body
Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen .
PMID:9111081
This step leads to rapid platelet aggregation which physically plugs ruptured endothelial cell surface (By similarity)
Integrin alpha-IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain (By similarity). Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen .
PMID:9111081
This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. Fibrinogen binding enhances SELP expression in activated platelets (By similarity).
ITGAV:ITGB3 binds to fractalkine (CX3CL1) and acts as its coreceptor in CX3CR1-dependent fractalkine signaling .
PMID:23125415 PMID:24789099
ITGAV:ITGB3 binds to NRG1 (via EGF domain) and this binding is essential for NRG1-ERBB signaling .
PMID:20682778
ITGAV:ITGB3 binds to FGF1 and this binding is essential for FGF1 signaling .
PMID:18441324
ITGAV:ITGB3 binds to FGF2 and this binding is essential for FGF2 signaling .
PMID:28302677
ITGAV:ITGB3 binds to IGF1 and this binding is essential for IGF1 signaling .
PMID:19578119
ITGAV:ITGB3 binds to IGF2 and this binding is essential for IGF2 signaling .
PMID:28873464
ITGAV:ITGB3 binds to IL1B and this binding is essential for IL1B signaling .
PMID:29030430
ITGAV:ITGB3 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1 .
PMID:18635536 PMID:25398877
ITGAV:ITGB3 acts as a receptor for fibrillin-1 (FBN1) and mediates R-G-D-dependent cell adhesion to FBN1 .
PMID:12807887
In brain, plays a role in synaptic transmission and plasticity. Involved in the regulation of the serotonin neurotransmission, is required to localize to specific compartments within the synapse the serotonin receptor SLC6A4 and for an appropriate reuptake of serotonin. Controls excitatory synaptic strength by regulating GRIA2-containing AMPAR endocytosis, which affects AMPAR abundance and composition (By similarity).
ITGAV:ITGB3 act as a receptor for CD40LG .
PMID:31331973
ITGAV:ITGB3 acts as a receptor for IBSP and promotes cell adhesion and migration to IBSP PMID:10640428
ATC B01AC17
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Tirofiban
Additional database identifiers
Drugs Product Database (DPD)
11752
ChemSpider
54912
BindingDB
50004058
PDB
AGG
ZINC
ZINC000003806104
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6138
GenAtlas
ITGA2B
GeneCards
ITGA2B
GenBank Gene Database
J02764
GenBank Protein Database
190068
Guide to Pharmacology
2441
UniProt Accession
ITA2B_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6156
GenAtlas
ITGB3
GeneCards
ITGB3
GenBank Gene Database
J02703
GenBank Protein Database
306786
Guide to Pharmacology
2457
UniProt Accession
ITB3_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72